ILMN intrinsic value
ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests
/PRNewswire/ -- ArcherDX, Inc. today announced a non-exclusive, multi-year partnership with Illumina, Inc. (NASDAQ: ILMN) intended to broaden access of next. . .
Illumina Inc. and Pacific Biosciences of California Inc. on Thursday said they have agreed to drop plans to merge. Under the merger agreement, announced Nov. . . .
You pay a high price for a company with near monopoly like Illumina. ILMN stock has 70% market share, but Its valuation is too high.
Illumina reported earnings per share of $1. 93 on revenue of $838M, the consensus between analysts was $1.4 per share on revenue of $871M.
The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
The unveiling of Veriseq NIPT v2 and Illumina's (ILMN) alliance with AnchorDx in the second quarter further raise investor confidence in the stock.
Illumina reported earnings per share of $1. 35 on revenue of $838M, the consensus between analysts was $1.34 per share on revenue of $835M.